ClinicalTrials.gg
CompletedNCT06868602Updated Mar 11, 2025

Effects of Regular Exercise and Psychoeducation on Quality of Life and Depression in the Treatment of Sarcopenia

An interventional study of psychoeducation and Exercise in Sarcopenia in Elderly, sponsored by Lokman Hekim Üniversitesi. Completed at 1 site in Turkey. Open to participants aged 60 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-03-11.

Sponsored by Lokman Hekim Üniversitesi · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 8 months after the study started (first participant enrolled Jun 2024, registered Feb 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
60 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 131 studies in Sarcopenia with a site in Turkey — 36 open to participants now, 43 under way, none of them phase 3. Sarcopenia · Turkey.

Enrollment
15th of 34
40 · median 40
Started
2024
with 20 others
No phase
32 of 131
6 open now
Registered
64th of 131
by date

Among the 131 studies in Sarcopenia with a site in Turkey, this one is the 15th largest by enrollment of the 34 interventional ones that give a count, is one of 21 that started in 2024, is one of 32 with no phase, and was the 64th registered.

Sarcopenia

1,334 studies on the registry are indexed under Sarcopenia; 418 are open to participants now.

Browse Sarcopenia studies →

Open to participants now

36 of the 131 studies in Sarcopenia with a site in Turkey are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 246 Sarcopenia studies recruiting now, 155 (63%) set no upper age limit and 32 (13%) stop at 75 or younger; 9 take children under 18; 62 take healthy volunteers.

This study: 60 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 131 studies in Sarcopenia with a site in Turkey, or all of them as a file.
02

Study summary

In this study, it was aimed to observe the effect of psychoeducation, which has not yet been included among the treatment methods of sarcopenia, which affects elderly individuals both physically and psychologically and has been proven to negatively affect their quality of life, on Quality of Life, Depression and Physical Function when applied with exercise therapy.

It is known that exercise programs applied in the treatment of sarcopenia, which has become a common problem in elderly individuals and is known as the trigger of most symptomatic diseases, have positive effects.

However, no psychoeducation program has been applied to date in the treatment of sarcopenia, which is thought to trigger psychological factors as well as physical factors.

In this direction, it is aimed to contribute to sarcopenia treatment and indirectly to geriatric rehabilitation programs according to the results we will obtain in sarcopenic individuals with the psychoeducation program, which we think is lacking.

In addition to all these, sarcopenia, which is a treatable diagnosis and one of the biggest obstacles to the independent life of elderly individuals, is thought to be a preventable condition with preventive rehabilitation programs.

Researchers believe that preventive rehabilitation programs will positively affect the amount spent on elderly care services, which constitute a large portion of our country's health expenses, and Researchers aim to support these issues with the results they will obtain.

Read the detailed description

This study was planned to examine the effectiveness of exercise and psychoeducation programs applied to sarcopenic individuals.

Sarcopenia, which causes muscle strength loss in elderly individuals, is shown as a risk factor for many negative outcomes ranging from fractures to death.

Sarcopenia, which is also shown as the cause of many metabolic diseases, is often a preventable disease, but it is seen that scientific studies on sarcopenia treatment in the academic field are not sufficient.

While the majority of the studies conducted include physiotherapy programs, the psychological dimension of the treatment has been ignored and although it has been associated with depression, no scientific study has been found that includes this psychoeducation program.

The physical problems experienced by sarcopenic individuals are basically movement disorders that occur due to muscle strength loss, along with deterioration in their quality of life and physical functions, and musculoskeletal system diseases.

However, sarcopenia is a multifaceted disease that is not only physical but also causes psychological diseases such as depression.

In addition, it is known that physical function loss, which is one of the symptoms of sarcopenia, has a negative effect on the level of depression, independent of sarcopenia.

In light of all this information, it is thought that if the treatment program prepared for sarcopenic individuals does not include a psychoeducation program together with the physiotherapy program, a part of the treatment will be incomplete.

This study, which researchers designed to investigate the psychoeducation program, the therapeutic effect of which is not yet known on sarcopenia, aims to contribute to this area.

It is aimed to reach a conclusion by comparing the differences between the Physical Function, Quality of Life and Depression parameters of the psychoeducation program combined with the exercise program in sarcopenic individuals and the sarcopenic individuals who only received the exercise program.

03

Conditions studied

  • Sarcopenia in Elderly

Keywords

  • sarcopenia
  • exercise
  • psychoeducation
04

Who can participate

Ages eligible
60 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Individuals aged 60 and over who have signed a consent form and agreed to volunteer for the study.
  • Individuals classified as sarcopenic according to the criteria of the European Working Group on Sarcopenia (EWGSOP2).
  • Individuals who scored 24 points or higher on the Standardized Mini Mental Test.

Exclusion criteria

Exclusion Criteria:

  • Individuals with neurological disease,
  • Individuals with advanced kidney disease,
  • Individuals with pacemakers,
  • Individuals with advanced vision and hearing problems,
  • Individuals with advanced dementia,
  • Individuals with orthopedic disabilities
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • No intervention
    control

    This group will be informed about exercise and psychoeducation only once after the sessions are completed.

  • Active comparator
    exercise

    Physical exercise will be performed for 45 minutes twice a week for eight weeks.

    Other: Exercise

  • Active comparator
    exercise and psychoeducation

    A 45-minute exercise program twice a week and a 45-minute psychoeducation program once a week will be implemented for 8 weeks.

    Other: psychoeducation · Other: Exercise

Interventions

  • Otherpsychoeducation

    Although the literature investigating the effectiveness of exercise programs on quality of life, physical function and depression in sarcopenic individuals is extensive, no studies have been found in which psychoeducation programs are applied to sarcopenic individuals and their effectiveness is investigated. In this planned study,Researchers aim to observe what kind of results will emerge and in what direction the psychoeducation program will shape the treatment by applying both exercise and psychoeducation programs to sarcopenic individuals.

    Also known as: exercise

  • OtherExercise

    Although the literature investigating the effectiveness of exercise programs on quality of life, physical function and depression in sarcopenic individuals is extensive, no studies have been found in which psychoeducation programs are applied to sarcopenic individuals and their effectiveness is investigated. In this planned study, Researchers aim to observe what kind of results will emerge and in what direction the psychoeducation program will shape the treatment by applying both exercise and psychoeducation programs to sarcopenic individuals.

06

What researchers measure

Primary outcomes

  1. TUG test

    A chair and a stopwatch are required for the test, which evaluates the risk of falls and mobility in the elderly. The test is performed with the shoes the individual always uses. A 3-meter area is determined in front of the chair. The individual is asked to get up from the chair, walk this distance, and sit down again.

    Time frame: Before treatment

  2. SF-12 Test

    It is an abbreviated form for assessing quality of life. This form, developed by Ware et al. (1995), is not specific to any age or type of disease, but is a scale that assesses the person's quality of life over the last four weeks. SF-12; It includes the sub-elements of physical functioning, physical role, pain, general health, emotional role, mental health, social functioning and vitality and consists of 12 questions.

    Time frame: Before treatment

  3. GDS

    This scale was developed by Yesavage et al. (1983). The Turkish adaptation of the scale was made by Ertan et al. The scale is self-reporting, aimed at the elderly, easy to answer and consists of 30 questions. A higher score indicates a higher level of depression.

    Time frame: Before treatment

  4. Bioelectrical impedance analysis (BIA)

    Bioelectrical impedance analysis (BIA) measurement; It is a non-invasive measurement. It takes advantage of the different resistance of different tissues in the body to currents. A weak electric current is directed to the body and the impedance is measured. It is used to estimate body composition parameters such as total body water and fat-free mass.

    Time frame: Before treatment

  5. SARC-F

    SARC-F; It allows health professionals to quickly and easily assess the risk of sarcopenia in primary health care. It asks 5 questions about "strength, assistance while walking, getting up from a chair, climbing stairs and falling". The SARC-F score range is from 0 to 10, with a score range of 0-3 representing a healthy condition and a score range of 4 and above representing a symptomatic condition.

    Time frame: Before treatment

  6. Standardized Mini Mental Test (SMMT)

    Mini Mental Test developed by Folstein et al. (1975) allows for cognitive assessment in a short time. In this respect, SMMT is a short, easy-to-apply and standardized test used to determine the cognitive level globally.

    Time frame: Before treatment , pre test only

  7. Handgrip strength assessment

    During the assessment, the individual is seated upright on a chair without surface support for the arm being assessed. The arm to be measured is positioned in a free position, with the knee angle and elbow angle at 90 degrees. The subject is asked to squeeze the dynamometer with their fingers as hard and tight as possible. The measurements are repeated 3 times, with 10 seconds between them and each measurement being no less than 5 seconds, and any interventions that may affect the measurements during the assessment are avoided.

    Time frame: Before treatment

Secondary outcomes

  1. TUG test

    A chair and a stopwatch are required for the test, which evaluates the risk of falls and mobility in the elderly. The test is performed with the shoes the individual always uses. A 3-meter area is determined in front of the chair. The individual is asked to get up from the chair, walk this distance, and sit down again.

    Time frame: Within a week of the end of treatment (within 1 week of the completion of the 8-week treatment)

  2. SF-12 Test

    It is an abbreviated form for assessing quality of life. This form, developed by Ware et al. (1995), is not specific to any age or type of disease, but is a scale that assesses the person's quality of life over the last four weeks. SF-12; It includes the sub-elements of physical functioning, physical role, pain, general health, emotional role, mental health, social functioning and vitality and consists of 12 questions.

    Time frame: Within a week of the end of treatment (within 1 week of the completion of the 8-week treatment)

  3. GDS

    This scale was developed by Yesavage et al. (1983). The Turkish adaptation of the scale was made by Ertan et al. The scale is self-reporting, aimed at the elderly, easy to answer and consists of 30 questions. A higher score indicates a higher level of depression.

    Time frame: Within a week of the end of treatment (within 1 week of the completion of the 8-week treatment)

  4. Bioelectrical impedance analysis (BIA)

    Bioelectrical impedance analysis (BIA) measurement; It is a non-invasive measurement. It takes advantage of the different resistance of different tissues in the body to currents. A weak electric current is directed to the body and the impedance is measured. It is used to estimate body composition parameters such as total body water and fat-free mass.

    Time frame: Within a week of the end of treatment (within 1 week of the completion of the 8-week treatment)

  5. Handgrip strength assessment

    During the assessment, the individual is seated upright on a chair without surface support for the arm being assessed. The arm to be measured is positioned in a free position, with the knee angle and elbow angle at 90 degrees. The subject is asked to squeeze the dynamometer with their fingers as hard and tight as possible. The measurements are repeated 3 times, with 10 seconds between them and each measurement being no less than 5 seconds, and any interventions that may affect the measurements during the assessment are avoided.

    Time frame: Within a week of the end of treatment (within 1 week of the completion of the 8-week treatment)

07

Study locations

1 site
  • Ondokuz Mayıs University
    Samsun, 55400, Turkey
08

References and documents

Individual participant data

Plan to share: No — All IPD collected

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2024 to primary completion in Jun 2024, 0 months.

Of 497 non-industry interventional studies with no phase under Sarcopenia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 34. This study's 0 months is below that.

Counting every sponsor, half of 509 studies reached it within 18 months; a quarter within 8 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2025
First posted
Mar 11, 2025
StartActual
Jun 1, 2024
Primary completionActual
Jun 15, 2024
CompletionActual
Sep 28, 2024
Last update
Mar 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06868602
Lead sponsor
Lokman Hekim Üniversitesi
Responsible party
Elif Asan (clinical physiotherapist, Lokman Hekim Üniversitesi) — Principal investigator
First posted
Mar 11, 2025
Start date
Jun 1, 2024
Primary completion
Jun 15, 2024
Completion
Sep 28, 2024
Last update
Mar 11, 2025

Study contacts

Esra Erdoğan
study director · Ondokuz Mayıs University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion